Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure

Journal of the American College of Cardiology

Volumn 32, Issue 5, 1998, Pages 1194-1200

  Watanabe, Hideki ^a,d   Kakihana, Masaaki ^b   Ohtsuka, Sadanori ^c   Sugishita, Yasuro ^c  

^a Kinu Medical Association Hospital   (Japan)

^b IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d KINU Medical Association Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

'ARTIST'; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLIC GMP; DOXAZOSIN; DOXAZOSIN MESYLATE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; METOPROLOL; METOPROLOL TARTRATE; NITRATE; PLACEBO; SUPEROXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; FOREARM BLOOD FLOW; HEART FAILURE; HUMAN; MALE; PLETHYSMOGRAPHY; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; THROMBOCYTE; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

EID: 0032212231     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00392-1     Document Type: Article

References (43)

1. Abrams J. Tolerance to organic nitrates. Circulation 1986;74:1181-5.
2. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
3. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-84.
4. Fung H-L. Solving the mystery of nitrate tolerance. A new scent on the trail? Circulation 1993;88:322-4.
5. Parker JD, Farrel B, Fenton T, Cohanim MA, Parker JO. Counterregulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
6. Dupuis J, Lalonde G, Lemieux R, Rouleau J. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
7. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-31.
8. Schröder H, Leitman D, Bennett B, Waldman S, Murad F. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther 1988;245:413-8.
9. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance. J Clin Invest 1995;95:187-94.
10. Dhalla A, Hill M, Singal P. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-14.
11. Packer M, Colucci WS, Sackner BJ, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
12. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group [see comments]. N Engl J Med 1996;334:1349-55.
13. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
14. Feuerstein GZ, Ruffolo RRJ. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17 Suppl B:24-9.
15. Ruffulo R, Gelai M, Heible J, Willette R, Nichols A. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38 Suppl 2:82-8.
16. Yue T-L, Cheny HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
17. Yue T-L, Mckenna PJ, Lysko PG, et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994;251:237-43.
18. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP: a potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.
19. Honma M, Satoh T, Takezawa J, Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small volume samples from blood and tissue. Biochem Med 1977;18:257-73.
20. Crandall LA, Leake CD, Loevenhart AS, Muehlberger CW. Acquired tolerance to and cross-tolerance between the nitrous and nitric acid esters and sodium nitrite in man. J Pharmacol Exp Ther 1931;41:103-19.
21. Elkayam U, Aronow WS. Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use. Drugs 1982;23:165-94.
22. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Int Med 1991;114:667-77.
23. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994;128:137-46.
24. Münzel T, Kurz S, Heitzer T, Harrison DG. New insights into mechanisms undrlying nitrate tolerance. Am J Cardiol 1996;77:24C-30C.
25. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol 1990;16:932-5.
26. Slack CJ, McLaughlin BE, Brien JF, Marks GS, Nakatsu K. Biotransformation of glyceryl trinitrate and isosorbide dinitrate in vascular smooth muscle made tolerant to organic nitrates. Can J Physiol Pharmacol 1989;67:1381-5.
27. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-9.
28. Needleman P, Johnson EMJ. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-15.
29. Feelisch M, Nack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30.
30. Bassenge E, Fink B. Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn Schmiedebergs Arch Pharmacol 1996;353:363-7.
31. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-80.
32. Elkayam U. Prevention of nitrate tolerance with concomitant administration of hydralazine. Can J Cardiol 1996;12 Suppl C17-21.
33. Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996;98:1465-70.
34. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997;96:2545-50.
35. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol 1998;31:1323-9.
36. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998;97:886-91.
37. Feuerstein GZ, Ruffolo RR, Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular rotection. Eur Heart J 1995;16 Suppl F:38-42.
38. Kramer JH, Weglicki WB. A hydroxylated analog of the β-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med 1996;21:813-25.
39. Bowen R, Haslam R. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood: role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1. J Cardiovasc Pharmacol 1991;17:424-33.
40. Pohl U, Busse R. EDRF increase cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989;65:1798-803.
41. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cyclic Nucleotide Protein Phosphory Res 1983;9:281-96.
42. Glass DB, Frey WH, Carr DW, Goldberg ND. Stimulation of human platelet guanylate cyclase by fatty acid. J Biol Chem 1977;252:1279-85.
43. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-601.